Guggenheim Maintains Buy on Twist Bioscience, Raises Price Target to $212

Guggenheim analyst Subbu Nambi has maintained a Buy rating on Twist Bioscience (NASDAQ: TWST) and raised the price target from $107 to $212. This adjustment reflects a positive outlook on the company's performance.